HARNESS
LIVE

Serial Number

79398079

Owner

Harness Therapeutics Limited

Attorney

Rebecca Liebowitz

Filing Date

Feb 19, 2024

Add to watchlist:

No watchlists yet
View on USPTO

HARNESS Trademark

Serial Number: 79398079 • Registration: 7895179

HARNESS is a trademark filed by Harness Therapeutics Limited on February 19, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Harness Therapeutics Limited (4 trademarks)

Minerva Building (B250),

Entity Type: 98

Trademark Details

Filing Date

February 19, 2024

Registration Date

August 19, 2025

Published for Opposition

June 3, 2025

Goods & Services

Scientific and technological services and research and design relating thereto namely scientific research services in the field of genomics; medical research services including the manipulation of biological reagents to be used for medical or therapeutic purposes; chemical and biological analysis and research services; scientific research into DNA and RNA; research and development into the creation of DNA and RNA; research and development services in the manufacture of synthetic DNA, RNA, genes and oligonucleotides for others; research, development, testing and analysis for scientific research purposes in the field of genomics, DNA and RNA sequencing, gene synthesis, gene identification, gene cloning, gene expression, gene mapping; scientific research in the field of molecular biology, next generation sequencing, high-throughput sequencing and bioinformatics; gene-editing services for scientific research purposes; DNA and RNA modelling services, namely, genetic mapping for scientific research purposes; gene engineering services; research and development services in the creation of genome libraries and collections of biologicals including chemicals and compounds; research and development services in creating libraries and collections of normal and mutated genes; scientific services research relating to the discovery, preclinical and clinical development of therapeutic products, namely, therapeutic DNA and RNA; consultancy and advisory services relating to the aforesaid services

Pharmaceutical preparations for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, neurological disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical and veterinary preparations for therapeutic purposes for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, neurological disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; biological, chemical and biochemical reagents for medical use; DNA, RNA, oligonucleotides, polynucleotides for medical use; gene editing enzymes for medical use; medical preparations containing therapeutic DNA and RNA, namely, nucleic and sequences for medical purposes; all of the foregoing excluding dietary and nutritional supplements

Chemicals for scientific purposes; chemicals for use in scientific research; chemicals, enzymes, biological preparations in the nature of DNA and RNA for scientific research use; chemicals for scientific research use in the preparation and creation of DNA and RNA; enzymes for scientific research purposes for use in the preparation and creation of DNA and RNA; molecular biology research tools in the nature of biological, chemical and biochemical reagents for research use

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 19, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 2, 2026 FICS
FINAL DISPOSITION PROCESSED
Mar 2, 2026 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 5, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 19, 2025 OPNS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 19, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Nov 19, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 19, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 19, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 3, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 3, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 28, 2025 NONP
WITHDRAWN FROM PUB - OG REVIEW QUERY
May 6, 2025 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 15, 2025 CNSA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 2, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Apr 2, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 2, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 2, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 2, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 2, 2025 COAR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 21, 2025 ADCH
ASSIGNED TO EXAMINER
Mar 19, 2025 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 14, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 14, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 14, 2025 TROA
ASSIGNED TO EXAMINER
Nov 30, 2024 DOCK
ASSIGNED TO EXAMINER
Nov 30, 2024 DOCK
REFUSAL PROCESSED BY IB
Oct 7, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 16, 2024 RFCS
REFUSAL PROCESSED BY MPU
Sep 16, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 13, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 12, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 9, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 24, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 24, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 20, 2024 REPR